Published in J Hepatol on June 23, 2008
Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol (2009) 3.90
Chemokines in the immunopathogenesis of hepatitis C infection. Hepatology (2009) 1.46
Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines (2011) 1.37
Emerging concepts in immunity to hepatitis C virus infection. J Clin Invest (2013) 1.12
Ribavirin exerts differential effects on functions of Cd4+ Th1, Th2, and regulatory T cell clones in hepatitis C. PLoS One (2012) 0.96
Retention of CD4+ CD25+ FoxP3+ regulatory T cells in the liver after therapy-induced hepatitis C virus eradication in humans. J Virol (2011) 0.92
HCV genotype-3a T cell immunity: specificity, function and impact of therapy. Gut (2012) 0.86
Negative regulation of hepatitis C virus specific immunity is highly heterogeneous and modulated by pegylated interferon-alpha/ribavirin therapy. PLoS One (2012) 0.83
HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin. World J Gastroenterol (2014) 0.81
Targeted deletion of FGL2 leads to increased early viral replication and enhanced adaptive immunity in a murine model of acute viral hepatitis caused by LCMV WE. PLoS One (2013) 0.80
Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-α and ribavirin therapy for chronic hepatitis C patients. J Gastroenterol (2011) 0.76
Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C. J Viral Hepat (2011) 0.76
Ribavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominance. World J Hepatol (2015) 0.75
Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes from patients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy? Clin Exp Immunol (2010) 0.75
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med (2015) 13.90
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology (2008) 4.26
Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol (2009) 3.90
Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol (2007) 3.83
Rare birds in North America: acute hepatitis C cohorts. Gastroenterology (2008) 3.45
An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology (2004) 3.18
Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest (2010) 3.15
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization. Liver Transpl (2014) 2.71
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology (2003) 2.64
Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection. J Infect Dis (2009) 2.53
Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl (2013) 2.48
Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology (2003) 2.38
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology (2006) 2.26
Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis (2003) 2.17
Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis (2007) 2.16
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl (2007) 2.08
Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era. Hepatology (2011) 2.01
Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology (2011) 1.94
Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J Exp Med (2005) 1.93
Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology (2015) 1.87
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence. Hepatology (2006) 1.78
Defective leukocyte GM-CSF receptor (CD116) expression and function in inflammatory bowel disease. Gastroenterology (2011) 1.73
Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology (2010) 1.67
Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients. Am J Med (2007) 1.66
Hepatitis C virus and lichen planus: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2004) 1.62
A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS One (2010) 1.62
Are HIV-infected patients candidates for liver transplantation? J Hepatol (2008) 1.59
Expansion of innate CD5pos B cells expressing high levels of CD81 in hepatitis C virus infected liver. J Hepatol (2003) 1.58
A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. Arch Intern Med (2003) 1.58
Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences. J Immunol (2008) 1.57
High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. Hepatology (2013) 1.56
The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance. Am J Gastroenterol (2008) 1.55
Spontaneous recovery in acute human hepatitis C virus infection: functional T-cell thresholds and relative importance of CD4 help. J Virol (2007) 1.50
Pretransplantation CD56(+) innate lymphocyte populations associated with severity of hepatitis C virus recurrence. Liver Transpl (2008) 1.50
Prevalence of HBV precore/core promoter variants in the United States. Hepatology (2003) 1.47
Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response. J Clin Invest (2009) 1.46
A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl (2002) 1.45
Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite. Liver Transpl (2003) 1.44
Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology (2007) 1.42
Race- and gender-related variation in natural killer p46 expression associated with differential anti-hepatitis C virus immunity. Hepatology (2012) 1.41
Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology (2007) 1.40
Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol (2007) 1.38
Myeloid suppressor cells induced by hepatitis C virus suppress T-cell responses through the production of reactive oxygen species. Hepatology (2012) 1.36
Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease. Hepatology (2004) 1.36
Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. Hepatology (2010) 1.33
Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design. J Infect Dis (2006) 1.31
Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology (2003) 1.30
Natural killer cells: primary target for hepatitis C virus immune evasion strategies? Liver Transpl (2006) 1.29
Functional suppression by FoxP3+CD4+CD25(high) regulatory T cells during acute hepatitis C virus infection. J Infect Dis (2008) 1.29
NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells. J Immunol (2003) 1.29
Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus. J Infect Dis (2010) 1.28
Regulation of virus-specific CD4+ T cell function by multiple costimulatory receptors during chronic HIV infection. J Immunol (2010) 1.28
Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS). AIDS Patient Care STDS (2009) 1.25
A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci U S A (2007) 1.24
Decrease in hepatic CD56(+) T cells and V alpha 24(+) natural killer T cells in chronic hepatitis C viral infection. J Hepatol (2002) 1.22
Mechanisms of Disease: HCV-induced liver injury. Nat Clin Pract Gastroenterol Hepatol (2007) 1.22
Comprehensive assessment of chemokine expression profiles by flow cytometry. J Clin Invest (2010) 1.21
Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C. J Hepatol (2008) 1.17
Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. Am J Gastroenterol (2009) 1.16
Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-kappaB-dependent signal transduction pathway. Arthritis Rheum (2006) 1.15
A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl (2005) 1.13
Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C. Hepatology (2011) 1.13
Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology (2010) 1.13
Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J Biol Chem (2013) 1.13
Emerging concepts in immunity to hepatitis C virus infection. J Clin Invest (2013) 1.12
HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo. J Invest Dermatol (2008) 1.11
Phenotypic and functional changes of cytotoxic CD56pos natural T cells determine outcome of acute hepatitis C virus infection. J Virol (2007) 1.08
A general method for nested RT-PCR amplification and sequencing the complete HCV genotype 1 open reading frame. Virol J (2005) 1.06
Assessing the validity of self-reported medication adherence in hepatitis C treatment. Ann Pharmacother (2007) 1.04
Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection. Gastroenterology (2009) 1.04
Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy. PLoS One (2008) 1.02
Interleukin (IL)-17/IL-22-producing T cells enriched within the liver of patients with chronic hepatitis C viral (HCV) infection. Dig Dis Sci (2011) 1.02
Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis (2010) 1.00